RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for RegeneRx Biopharmaceuticals and Clovis Oncology, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RegeneRx Biopharmaceuticals 0 0 0 0 N/A
Clovis Oncology 1 5 8 0 2.50

Clovis Oncology has a consensus target price of $25.50, suggesting a potential upside of 323.59%. Given Clovis Oncology’s higher probable upside, analysts clearly believe Clovis Oncology is more favorable than RegeneRx Biopharmaceuticals.

Risk & Volatility

RegeneRx Biopharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of RegeneRx Biopharmaceuticals shares are held by institutional investors. Comparatively, 91.7% of Clovis Oncology shares are held by institutional investors. 10.9% of RegeneRx Biopharmaceuticals shares are held by company insiders. Comparatively, 8.3% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares RegeneRx Biopharmaceuticals and Clovis Oncology’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RegeneRx Biopharmaceuticals $70,000.00 273.35 -$1.99 million N/A N/A
Clovis Oncology $95.39 million 3.45 -$368.01 million ($7.07) -0.85

RegeneRx Biopharmaceuticals has higher earnings, but lower revenue than Clovis Oncology.


This table compares RegeneRx Biopharmaceuticals and Clovis Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RegeneRx Biopharmaceuticals -1,790.79% N/A -198.90%
Clovis Oncology -332.18% -372.68% -49.10%


Clovis Oncology beats RegeneRx Biopharmaceuticals on 7 of the 11 factors compared between the two stocks.

RegeneRx Biopharmaceuticals Company Profile

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive News & Ratings for RegeneRx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RegeneRx Biopharmaceuticals and related companies with's FREE daily email newsletter.